List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9420567/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer. JAMA Oncology, 2022, 8, e215445.	7.1	127
2	Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial. International Journal of Radiation Oncology Biology Physics, 2022, 113, 80-91.	0.8	5
3	Differences in stem cell marker and osteopontin expression in primary and recurrent glioblastoma. Cancer Cell International, 2022, 22, 87.	4.1	8
4	Comparing Iridium-192 with Cobalt-60 sources in high-dose-rate brachytherapy boost for localized prostate cancer. Acta Oncológica, 2022, 61, 714-719.	1.8	1
5	Propensity score-matched analysis comparing dose-escalated intensity-modulated radiation therapy versus external beam radiation therapy plus high-dose-rate brachytherapy for localized prostate cancer. Strahlentherapie Und Onkologie, 2022, , 1.	2.0	4
6	Pasotuxizumab, a BiTE [®] immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings. Immunotherapy, 2021, 13, 125-141.	2.0	72
7	Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis. Strahlentherapie Und Onkologie, 2021, 197, 124-132.	2.0	11
8	Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial. European Journal of Cancer, 2021, 144, 281-290.	2.8	6
9	Chemoradiotherapy by intensity-modulated radiation therapy with simultaneous integrated boost in locally advanced or oligometastatic non-small-cell lung cancer—aÂtwo center experience. Strahlentherapie Und Onkologie, 2021, 197, 405-415.	2.0	2
10	Salvage Mastectomy Versus Second Conservative Treatment for Second Ipsilateral Breast Tumor Event: A Propensity Score-Matched Cohort Analysis of the GEC-ESTRO Breast Cancer Working Group Database. International Journal of Radiation Oncology Biology Physics, 2021, 110, 452-461.	0.8	30
11	Comparison of treatment plans for hypofractionated highâ€dose prostate cancer radiotherapy using the Varian Halcyon and the Elekta Synergy platforms. Journal of Applied Clinical Medical Physics, 2021, 22, 262-270.	1.9	3
12	Cone beam CT-based dose accumulation and analysis of delivered dose to the dominant intraprostatic lesion in primary radiotherapy of prostate cancer. Radiation Oncology, 2021, 16, 205.	2.7	11
13	Comparison of sliding window and field-in-field techniques for tangential whole breast irradiation using the Halcyon and Synergy Agility systems. Radiation Oncology, 2021, 16, 213.	2.7	3
14	Predictors for the utilization of social service counseling by prostate cancer patients. Supportive Care in Cancer, 2021, , 1.	2.2	1
15	Two-Weekly High-Dose-Rate Brachytherapy Boost After External Beam Radiotherapy for Localized Prostate Cancer: Long-Term Outcome and Toxicity Analysis. Frontiers in Oncology, 2021, 11, 764536.	2.8	2
16	The role of beam density and arrangement in non-coplanar IMRT exemplified by the irradiation of brain tumors – Parallels to computed tomographic imaging. Physica Medica, 2021, , .	0.7	0
17	RADIANCE – Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial. Clinical and Translational Radiation Oncology, 2020, 23, 43-49.	1.7	16
18	Feasibility of 4D T2* quantification in the lung with oxygen gas challenge in patients with non-small cell lung cancer. Physica Medica, 2020, 72, 46-51.	0.7	2

#	Article	IF	CITATIONS
19	Evaluation of intrafraction prostate motion tracking using the Clarity Autoscan system for safety margin validation. Zeitschrift Fur Medizinische Physik, 2020, 30, 135-141.	1.5	8
20	Non-rigid image registration of 4D-MRI data for improved delineation of moving tumors. BMC Medical Imaging, 2020, 20, 41.	2.7	4
21	T-Staging and Target Volume Definition by Imaging in GI Tumors. Medical Radiology, 2020, , 203-220.	0.1	0
22	Patient-Reported Outcomes–Secondary Analysis of the SCORE-2 Trial Comparing 4 Gy × 5 to 3 Gy × 10 for Metastatic Epidural Spinal Cord Compression. International Journal of Radiation Oncology Biology Physics, 2019, 105, 760-764.	0.8	9
23	Impact of beam configuration on VMAT plan quality for Pinnacle3Auto-Planning for head and neck cases. Radiation Oncology, 2019, 14, 12.	2.7	7
24	Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma. Radiation Oncology, 2019, 14, 227.	2.7	6
25	The Radiosensitizing Effect of Zinc Oxide Nanoparticles in Sub-Cytotoxic Dosing Is Associated with Oxidative Stress In Vitro. Materials, 2019, 12, 4062.	2.9	6
26	Properties of the anisotropy of dose contributions: A planning study on prostate cases. Medical Physics, 2019, 46, 419-425.	3.0	0
27	Hypoxia induces differential expression patterns of osteopontin and CD44 in colorectal carcinoma. Oncology Reports, 2018, 39, 442-448.	2.6	10
28	Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 834-844.	10.7	102
29	Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients. British Journal of Cancer, 2018, 118, 785-792.	6.4	34
30	Stable and efficient retrospective 4D-MRI using non-uniformly distributed quasi-random numbers. Physics in Medicine and Biology, 2018, 63, 075002.	3.0	15
31	Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10. Radiotherapy and Oncology, 2018, 126, 257-262.	0.6	19
32	Combination of salinomycin and radiation effectively eliminates head and neck squamous cell carcinoma cells inÃ ⁻ ¿½vitro. Oncology Reports, 2018, 39, 1991-1998.	2.6	3
33	MAGE-A9 in head and neck cancer: Prognostic value and preclinical findings in the context of irradiation. Molecular and Clinical Oncology, 2018, 8, 513-519.	1.0	3
34	Desynchronization of Cartesian kâ€space sampling and periodic motion for improved retrospectively selfâ€gated 3D lung MRI using quasiâ€random numbers. Magnetic Resonance in Medicine, 2017, 77, 787-793.	3.0	8
35	Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 259-268.	10.7	220
36	Perioperative changes in osteopontin and TGFÎ ² 1 plasma levels and their prognostic impact for radiotherapy in head and neck cancer. BMC Cancer, 2017, 17, 6.	2.6	4

#	Article	IF	CITATIONS
37	Evaluation of a software module for adaptive treatment planning and re-irradiation. Radiation Oncology, 2017, 12, 205.	2.7	8
38	68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT. Clinical Nuclear Medicine, 2016, 41, 515-521.	1.3	165
39	GEC-ESTRO multicenter phase 3-trial: Accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: Early toxicity and patient compliance. Radiotherapy and Oncology, 2016, 120, 119-123.	0.6	90
40	Initial results for patient setup verification using transperineal ultrasound and cone beam CT in external beam radiation therapy of prostate cancer. Radiation Oncology, 2016, 11, 147.	2.7	11
41	Changes in penile bulb dose when using the Clarity transperineal ultrasound probe: A planning study. Practical Radiation Oncology, 2016, 6, e337-e344.	2.1	6
42	5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet, The, 2016, 387, 229-238.	13.7	578
43	Influence of hypoxia and irradiation on osteopontin expression in head and neck cancer and glioblastoma cell lines. Radiation Oncology, 2015, 10, 167.	2.7	12
44	A prospective study on histone γ-H2AX and 53BP1 foci expression in rectal carcinoma patients: correlation with radiation therapy-induced outcome. BMC Cancer, 2015, 15, 856.	2.6	21
45	Distinct increased outliers among 136 rectal cancer patients assessed by γH2AX. Radiation Oncology, 2015, 10, 36.	2.7	10
46	Tumour delineation in oesophageal cancer – A prospective study of delineation in PET and CT with and without endoscopically placed clip markers. Radiotherapy and Oncology, 2015, 116, 269-275.	0.6	23
47	Actin cytoskeleton organization, cell surface modification and invasion rate of 5 glioblastoma cell lines differing in PTEN and p53 status. Experimental Cell Research, 2015, 330, 346-357.	2.6	28
48	O-(2-[18F]fluoroethyl)-l-tyrosine uptake is an independent prognostic determinant in patients with glioma referred for radiation therapy. Annals of Nuclear Medicine, 2014, 28, 154-162.	2.2	9
49	Generation of prostate IMAT plans adaptable to the inter-fractional changes of patient geometry. Physics in Medicine and Biology, 2014, 59, 1947-1962.	3.0	3
50	Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines under Normoxic and Hypoxic Conditions. Breast Cancer: Basic and Clinical Research, 2014, 8, BCBCR.S13693.	1.1	35
51	Radiosensitivity in breast cancer assessed by the histone Î ³ -H2AX and 53BP1 foci. Radiation Oncology, 2013, 8, 98.	2.7	62
52	Hypoxia induced CA9 inhibitory targeting by two different sulfonamide derivatives including Acetazolamide in human Glioblastoma. Bioorganic and Medicinal Chemistry, 2013, 21, 3949-3957.	3.0	51
53	Studies on the role of osteopontin-1 in endometrial cancer cell lines. Strahlentherapie Und Onkologie, 2013, 189, 1040-1048.	2.0	7
54	Influence of osteopontin silencing on survival and migration of lung cancer cells. Strahlentherapie Und Onkologie, 2013, 189, 62-67.	2.0	10

#	Article	IF	CITATIONS
55	Radiosensitization of Glioblastoma Cell Lines by the Dual PI3K and mTOR Inhibitor NVP-BEZ235 Depends on Drug-Irradiation Schedule. Translational Oncology, 2013, 6, 169-IN16.	3.7	51
56	Towards automated on-line adaptation of 2-Step IMRT plans: QUASIMODO phantom and prostate cancer cases. Radiation Oncology, 2013, 8, 263.	2.7	4
57	Hsp90 inhibitor NVP-AUY922 enhances radiation sensitivity of tumor cell lines under hypoxia. Cancer Biology and Therapy, 2012, 13, 425-434.	3.4	22
58	Micronucleus formation kinetics in buccal mucosa cells of head and neck cancer patients undergoing radiotherapy. Toxicology Letters, 2012, 212, 33-37.	0.8	13
59	Hsp90 Inhibitors NVP-AUY922 and NVP-BEP800 May Exert a Significant Radiosensitization on Tumor Cells along with a Cell Type-Specific Cytotoxicity. Translational Oncology, 2012, 5, 356-IN16.	3.7	20
60	A multi-institution evaluation of deformable image registration algorithms for automatic organ delineation in adaptive head and neck radiotherapy. Radiation Oncology, 2012, 7, 90.	2.7	78
61	Gene expression inhibition of N-Myc downregulated gene 1 (NDRG1) monitoring and facilitation via transfectional transfer of NDRG1-siRNA constructs into- in vitro-cultured human glioblastoma cells. , 2011, , .		Ο
62	Toxicity after Intensity-Modulated, Image-Guided Radiotherapy for Prostate Cancer. Strahlentherapie Und Onkologie, 2010, 186, 535-543.	2.0	58
63	Semi-robotic 6 degree of freedom positioning for intracranial high precision radiotherapy; first phantom and clinical results. Radiation Oncology, 2010, 5, 42.	2.7	26
64	Modulation of Carbonic Anhydrase 9 (CA9) in Human Brain Cancer. Current Pharmaceutical Design, 2010, 16, 3288-3299.	1.9	49
65	The cohesin-interacting protein, precocious dissociation of sisters 5A/sister chromatid cohesion protein 112, is up-regulated in human astrocytic tumors. International Journal of Molecular Medicine, 2010, 27, 39-51.	4.0	12
66	Dose–response relationship for radiation-induced pneumonitis after pulmonary stereotactic body radiotherapy. Radiotherapy and Oncology, 2010, 97, 65-70.	0.6	147
67	Absence of GAPDH regulation in tumor-cells of different origin under hypoxic conditions in – vitro. BMC Research Notes, 2009, 2, 8.	1.4	32
68	Radiotherapy in adrenocortical carcinoma. Cancer, 2009, 115, 2816-2823.	4.1	165
69	Is ad-hoc plan adaptation based on 2-Step IMRT feasible?. Radiotherapy and Oncology, 2009, 93, 266-272.	0.6	12
70	MO-D-BRB-09: IMRT Ad-Hoc Adaption - Initial Results for Prostate: A Retrospective Planning Study. Medical Physics, 2009, 36, 2694-2694.	3.0	0
71	Intra-fractional uncertainties in image-guided intensity-modulated radiotherapy (IMRT) of prostate cancer. Strahlentherapie Und Onkologie, 2008, 184, 668-673.	2.0	51
72	Influence of retrospective sorting on image quality in respiratory correlated computed tomography. Radiotherapy and Oncology, 2007, 85, 223-231.	0.6	39

#	Article	IF	CITATIONS
73	Modulation of Glucose Metabolism Inhibits Hypoxic Accumulation of Hypoxia-Inducible Factor-1α (HIF-1α). Strahlentherapie Und Onkologie, 2007, 183, 366-373.	2.0	31
74	Nonrigid Patient Setup Errors in the Head-and-Neck Region. Strahlentherapie Und Onkologie, 2007, 183, 506-511.	2.0	59
75	Efficacy of Adjuvant Radiotherapy of the Tumor Bed on Local Recurrence of Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4501-4504.	3.6	224
76	Triplex-forming oligodeoxynucleotides targeting survivin inhibit proliferation and induce apoptosis of human lung carcinoma cells. Cancer Gene Therapy, 2003, 10, 403-410.	4.6	39
77	Targeting bcl-2 by Triplex-Forming Oligonucleotide—A Promising Carrier for Gene–Radiotherapy. Cancer Biotherapy and Radiopharmaceuticals, 2003, 18, 17-26.	1.0	17
78	Oxygen-dependent regulation of NDRG1 in human glioblastoma cells in vitro and in vivo. Oncology Reports, 1994, 21, 237.	2.6	15
79	Rapid detection of the hypoxia-regulated CA-IX and NDRG1 gene expression in different glioblastoma cells in vitro. Oncology Reports, 1994, 20, 413.	2.6	9